Companies Corona Virus Health Indian Subcontinent Industries Life Science medical

Cipremi : COVID-19 treatment drug from Cipla available by July 10

Pharma Company  Cipla Ltd is looking to make the generic version of US-based Gilead Sciences’ anti-viral drug remdesivir available in India in the next 8-10 days and price it less than ₹ 5,000 per vial Gilead Sciences extended a voluntary non-exclusive license to Cipla in May to manufacture and market Cipla’s generic version of remedisvir Read More…

Corona Virus Health medical

Gilead injectable drug to treat hospitalised Covid-19 patients

Hyderabad-based Hetero will launch remdesivir, an injectable drug from Gilead, to treat hospitalised Covid-19 patients within this week. The company will first make the drug available in the main disease burden areas of Maharashtra and Delhi under the brand Covifor.   A single dose vial is likely to cost between Rs 5,000-6000, the company said. Read More…

America China Companies Corona Virus Industries Life Science Science

Remdesivir has set a new standard of care for COVID-19 patients : USA

[splco_heading size=”15″ align=”left” margin=”30″]The announcement of remdesivir being a possible drug treatment against the deadly virus follows closely on research published in the Journal of Biological Chemistry, with scientists at the University of Alberta showing the drug is highly effective in stopping the replication mechanism of COVID-19.[/splco_heading]   Chair of medical microbiology and immunology at Read More…